Elbasvir/Grazoprevir Hydrate

艾尔巴韦/格拉瑞韦

Report date: 2026/04/08 20:02:35

Base Information

Drug NameElbasvir/Grazoprevir Hydrate
Drug Alias NameElbasvir and Grazoprevir艾尔巴维/格拉瑞维艾尔巴韦•格拉瑞韦Grazoprevir/Elbasvir艾尔巴韦和格拉瑞韦 +[11] 
ClassificationSmall molecules
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsNonstructural protein 5AHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsFibrosisMetabolic SyndromeLung Diseases +[9] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2016/01/28
Country/TerritoryUnited StatesVietnamSweden +[15] 
CombinationsYes Grazoprevir HydrateElbasvir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme BvUniversity Of PennsylvaniaMerck Sharp & Dohme LLC
Inactive CompaniesRadboud University Medical CenterMerck Sharp & Dohme CorpMerck & Co Inc +[8] 
Active IndicationsLung DiseasesHepatitis C, Chronic
Inactive IndicationsFibrosisMetabolic SyndromeLiver Cirrhosis +[7] 

Other Information

ATC CodeJ05AP54
Related LinksWikipediaKEGG